A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

NCT04300556 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

182

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Farletuzumab ecteribulin
DRUG: Prednisone
DRUG: Prednisolone
DRUG: Dexamethasone
DRUG: Lenvatinib

Sponsor

Eisai Inc.